04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
20:46 , Oct 19, 2018 |  BioCentury  |  Finance

Taiho ups its stakes

After bumping up its evergreen fund from $50 million to $300 million, Taiho Ventures LLC plans to increase its stakes in its portfolio companies. The strategic venture arm of Taiho Pharmaceutical Co. Ltd. launched in...
18:26 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Taiho Ventures increases investment pool to $300M

Taiho Ventures LLC increased its investment pool to $300 million from $50 million. The firm said it will focus the additional funds on oncology startups with drug discovery capabilities or unique platform technologies. Taiho Pharmaceutical...
20:55 , Oct 16, 2018 |  BC Extra  |  Financial News

Taiho Ventures ups investments to $300M, to focus on oncology

Taiho Ventures LLC increased its investment pool to $300 million from $50 million. Taiho Ventures said it will focus the additional funds on oncology startups with drug discovery capabilities or unique platform technologies. Taiho Pharmaceutical...
16:14 , Jul 20, 2018 |  BC Week In Review  |  Company News

Taiho exercises option for AB928

Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) exercised an option to develop and commercialize AB928 from cancer company Arcus Biosciences Inc. (NYSE:RCUS) in Japan and other Asian territories, excluding China. Arcus will receive an option exercise...
17:49 , May 11, 2018 |  BC Week In Review  |  Clinical News

Arcus reports Phase I safety data for cancer candidate AB928

Arcus Biosciences Inc. (NYSE:RCUS) reported data from 85 healthy volunteers in a Phase I trial showing that single and multiple ascending doses of cancer candidate AB928 were well tolerated. Data were presented at the American...
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
18:00 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Arcus raises upsized $120M IPO

Arcus Biosciences Inc. (NYSE:RCUS) raised on March 14 $120 million through the sale of 8 million shares at $15 in an upsized IPO underwritten by Citigroup, Goldman Sachs and Leerink. The IPO price valued Arcus...
17:49 , Mar 15, 2018 |  BC Extra  |  Financial News

Modest first-day pop for Arcus after upsized $120M IPO

Arcus Biosciences Inc. (NYSE:RCUS) climbed $2.08 (14%) to $17.08 on Thursday after raising $120 million through the sale of 8 million shares at $15 in an upsized IPO underwritten by Citigroup, Goldman Sachs and Leerink....
20:28 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Immuno-oncology play Arcus raises $107M

On Nov. 13, immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV. New investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling...